Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price rises 2.53% to Rs 2,395
- September 29, 2026
- Posted by: Kunal Singla
- Category: News
Glenmark Pharmaceuticals Ltd. Share Price is Rs 2,395, up 2.53% today, with a market capitalisation of Rs 67,254.14 crore. According to latest Univest data, the price rise is confirmed, but no company-specific catalyst is established.
Glenmark Pharmaceuticals Ltd. Share Price is moving higher today, with the stock last traded at Rs 2,395 after gaining Rs 59 from the previous close of Rs 2,336. The company’s market capitalisation stands at Rs 67,254.14 crore, placing Glenmark Pharmaceuticals Ltd. Share Price in active focus across market updates and stock news. Univest data confirms the move itself, though no company-specific trigger has been identified.
Glenmark Pharmaceuticals Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,395 |
| Previous Close | Rs 2,336 |
| Today's Move | Rs 59 (+2.53%) |
| Open | Rs 2,322.65 |
| High | Rs 2,395 |
| Low | Rs 2,290.6 |
| Market Capitalisation | Rs 67,254.14 crore |
| Market Cap Category | Large Cap |
Glenmark Pharmaceuticals Ltd. (GLENMARK) rose to Rs 2,395 from the previous close of Rs 2,336, a move of Rs 59 or 2.53%. The stock opened at Rs 2,322.65, reached a high of Rs 2,395, recorded a low of Rs 2,290.6.
Glenmark Pharmaceuticals Ltd. Share Price rose 2.53% today, adding Rs 59 from the previous close and touching Rs 2,395 as the day’s high. The stock opened at Rs 2,322.65 and moved between Rs 2,290.6 and Rs 2,395 during the current session, with market capitalisation at Rs 67,254.14 crore.
That price action shows a straightforward intraday gain in Glenmark Pharmaceuticals Ltd. Share Price. The stock traded above the previous close and reached the upper end of the day range, which makes the share price rise easy to verify without needing any extra narrative. Investors following Glenmark Pharmaceuticals Ltd. Share Price, Glenmark Pharmaceuticals Ltd. Share Price Today and Glenmark Pharmaceuticals Ltd. Share Price Live can note that the move is entirely anchored in the listed numbers. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established. The next step is to see whether the valuation and operating ratios support the current market interest.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 67,254.14 crore |
| P/E Ratio | 36.67x |
| P/B Ratio | 6.01x |
| ROE | 14.1% |
| ROCE | 20.35% |
| EPS | Rs 63.7 |
| Book Value Per Share | Rs 388.43 |
| Dividend Yield | 0.11% |
Glenmark Pharmaceuticals Ltd. (GLENMARK) fundamental metrics show P/E 36.67x, P/B 6.01x, ROE 14.1%, ROCE 20.35%. Read together, these ratios describe the company’s position rather than a recommendation.
Glenmark Pharmaceuticals Ltd. has a market capitalisation of Rs 67,254.14 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 36.67x, P/B at 6.01x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 14.1% and ROCE of 20.35%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 63.7, book value per share of Rs 388.43, dividend yield of 0.11%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.59x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 36.67x |
| Benchmark Median P/E | 32.59x |
| Benchmark Average P/E | 49x |
| Benchmark P/E Range | 3.46x to 707.31x |
| Company P/B Ratio | 6.01x |
| Benchmark Median P/B | 2.88x |
| Company ROE | 14.1% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 20.35% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 67,254.14 crore |
| Benchmark Median Market Cap | Rs 783.26 crore |
Glenmark Pharmaceuticals Ltd. (GLENMARK) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 36.67x, which is above the benchmark median of 32.59x, a difference of +12.52%. The P/E comparison frames valuation; it is not a signal to buy or sell.
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROE of 14.1%, which is above the benchmark median of 11.7%, a difference of +20.51%. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a ROCE of 20.35%, which is above the benchmark median of 13.61%, a difference of +49.52%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,44,716.74 | 36.5 | 5.1 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,55,115.31 | 86.51 | 14.33 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,89,613.38 | 84.92 | 20.64 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,19,899.96 | 26.79 | 4.48 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,12,875.68 | 33.29 | 3.19 | 11.83 | 16 |
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a P/E ratio of 36.67x compared with the displayed peer median of 36.5x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 14.1% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 20.35% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 67,254.14 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Glenmark Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd. Share Price rose 2.53% today and traded above the previous close.
- The stock touched Rs 2,395 during the session, which is the day’s high and the last traded price.
- Glenmark Pharmaceuticals Ltd. Share Price is supported by ROE of 14.1% and ROCE of 20.35%.
- The P/E of 36.67 and P/B of 6.01 place the stock above the industry median on valuation.
- Its Healthcare and Pharmaceuticals & Drugs setting gives additional context for Glenmark Pharmaceuticals Ltd. Stock Performance.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. operates in Healthcare and is part of the Pharmaceuticals & Drugs industry. The company is tracked closely because Glenmark Pharmaceuticals Ltd. Share Price reflects both its business scale and its operating ratios. With a market capitalisation of Rs 67,254.14 crore, the company sits among well-followed listed pharmaceutical names on NSE and BSE.
Glenmark Pharmaceuticals Ltd. Share Price is relevant for investors who monitor company fundamentals as well as daily price movement. The business operates in a sector where earnings quality, capital efficiency and valuation usually shape market attention. In that setting, Glenmark Pharmaceuticals Ltd. Stock Analysis often revolves around P/E, P/B, ROE, ROCE, EPS, book value and dividend yield. Univest tracks these factors so readers can connect Glenmark Pharmaceuticals Ltd. Share Price Today with company context rather than looking at the daily move in isolation. Glenmark Pharmaceuticals Ltd. Share News today remains tied to verified price action and financial metrics, not to speculation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Glenmark Pharmaceuticals Ltd. Share Price rising today?
Ans. Glenmark Pharmaceuticals Ltd. Share Price is rising today because it is trading Rs 59 above the previous close, up 2.53%. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established.
What is the current Glenmark Pharmaceuticals Ltd. Share Price?
Ans. Glenmark Pharmaceuticals Ltd. Share Price is Rs 2,395. The stock has moved above the previous close of Rs 2,336 and is trading near the day’s high, which also stands at Rs 2,395.
What is Glenmark Pharmaceuticals Ltd. Share Price Today movement?
Ans. Glenmark Pharmaceuticals Ltd. Share Price Today shows a gain of 2.53%, or Rs 59. The stock opened at Rs 2,322.65 and moved between Rs 2,290.6 and Rs 2,395 during the current session.
What is Glenmark Pharmaceuticals Ltd. market capitalisation?
Ans. Glenmark Pharmaceuticals Ltd. Market Cap is Rs 67,254.14 crore. This places the company within the Healthcare sector and gives scale context to Glenmark Pharmaceuticals Ltd. Share Price alongside valuation and peer comparisons.
How does Glenmark Pharmaceuticals Ltd. compare on valuation?
Ans. Glenmark Pharmaceuticals Ltd. Share Price is backed by a P/E of 36.67 and a P/B of 6.01. Both are above the industry median, while ROE and ROCE are also above benchmark levels.
What do ROE and ROCE show for Glenmark Pharmaceuticals Ltd.?
Ans. Glenmark Pharmaceuticals Ltd. reports ROE of 14.1% and ROCE of 20.35%. That means capital efficiency is stronger than shareholder return, and both ratios sit above the industry median in the same industry benchmark.
How does Glenmark Pharmaceuticals Ltd. compare with peers?
Ans. Glenmark Pharmaceuticals Ltd. Share Price sits below larger peers on market cap, but its P/E is close to Sun Pharmaceutical Industries Ltd. and above Cipla Ltd. and Zydus Lifesciences Ltd. ROCE is also comparatively strong.
Should investors track Glenmark Pharmaceuticals Ltd. Share Price on Univest?
Ans. Yes, Glenmark Pharmaceuticals Ltd. Share Price can be tracked on Univest for live price, valuation ratios, market capitalisation and company context. It is useful for monitoring price action alongside fundamentals and sector comparison.
Track Glenmark Pharmaceuticals Ltd. Share Price on Univest
Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
You can track Glenmark Pharmaceuticals Ltd. Share Price on Univest for live updates, key ratios, market capitalisation, 52-week levels and company insights. Univest brings Glenmark Pharmaceuticals Ltd. Share Price, valuation and sector context together in one place for easier monitoring.
